

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 February 2024 (08.02.2024)



(10) International Publication Number
WO 2024/028782 A1

(51) International Patent Classification:

A61P 3/10 (2006.01) A61P 35/00 (2006.01)
A61K 31/501 (2006.01) C07D 237/20 (2006.01)
A61P 9/00 (2006.01) C07D 401/12 (2006.01)
A61P 19/02 (2006.01)

(21) International Application Number:

PCT/IB2023/057819

(22) International Filing Date:

02 August 2023 (02.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/370,300 03 August 2022 (03.08.2022) US
PCT/CN2023/097282
30 May 2023 (30.05.2023) CN

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **GE, Xiaobin**; Suzhou Novartis Technical Development Co., Ltd., 18-1 Tonglian Road Bixi subdistrict Changshu, Jiangsu (CN). **MATTES, Henri**; 958 quartier le Cadeton, 83570 Monfort sur Argens (FR). **SHI, Zhicong**; China Novartis Institutes for Biomedical Research Co., Ltd., 4218 Jinke Road, Pudong New Area, Shanghai (CN). **XIA, Mei**; China Novartis Institutes for Biomedical Research Co., Ltd., 4218 Jinke Road, Pudong New Area, Shanghai (CN). **YE, Ning**; Suzhou Novartis Technical Development Co., Ltd., 18-1 Tonglian Road Bixi subdistrict Changshu, Jiangsu (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: NLRP3 INFLAMMASOME INHIBITORS

(57) Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of formula (I): wherein R¹, R², R³, R⁴ and R⁵ are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.



WO 2024/028782 A1